VHL-HIF-2α axis-induced SEMA6A upregulation stabilized β-catenin to drive clear cell renal cell carcinoma progression
-
Published:2023-02-04
Issue:2
Volume:14
Page:
-
ISSN:2041-4889
-
Container-title:Cell Death & Disease
-
language:en
-
Short-container-title:Cell Death Dis
Author:
Ji Jing, Xu Yuxin, Xie Mengru, He Xingbei, Ren Dexu, Qiu Teng, Liu Wenwen, Chen Zefeng, Shi Wen, Zhang Zhen, Wang Xiujun, Wang Weiling, Ma Jinming, Qian Qilan, Jing Aixin, Ma Xinhui, Qin Jingting, Ding Yuanyuan, Geng Ting, Yang Jiayan, Sun Zhichao, Liu Wei, Liu Shunfang, Liu BinORCID
Abstract
AbstractSEMA6A is a multifunctional transmembrane semaphorin protein that participates in various cellular processes, including axon guidance, cell migration, and cancer progression. However, the role of SEMA6A in clear cell renal cell carcinoma (ccRCC) is unclear. Based on high-throughput sequencing data, here we report that SEMA6A is a novel target gene of the VHL-HIF-2α axis and overexpressed in ccRCC. Chromatin immunoprecipitation and reporter assays revealed that HIF-2α directly activated SEMA6A transcription in hypoxic ccRCC cells. Wnt/β-catenin pathway activation is correlated with the expression of SEMA6A in ccRCC; the latter physically interacted with SEC62 and promoted ccRCC progression through SEC62-dependent β-catenin stabilization and activation. Depletion of SEMA6A impaired HIF-2α-induced Wnt/β-catenin pathway activation and led to defective ccRCC cell proliferation both in vitro and in vivo. SEMA6A overexpression promoted the malignant phenotypes of ccRCC, which was reversed by SEC62 depletion. Collectively, this study revealed a potential role for VHL-HIF-2α-SEMA6A-SEC62 axis in the activation of Wnt/β-catenin pathway. Thus, SEMA6A may act as a potential therapeutic target, especially in VHL-deficient ccRCC.
Funder
National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference34 articles.
1. Li RG, Deng H, Liu XH, Chen ZY, Wan SS, Wang L. Histone methyltransferase G9a promotes the development of renal cancer through epigenetic silencing of tumor suppressor gene SPINK5. Oxid Med Cell Longev. 2021;2021:6650781. 2. Solarek W, Czarnecka AM, Escudier B, Bielecka ZF, Lian F, Szczylik C. Insulin and IGFs in renal cancer risk and progression. Endocr Relat Cancer. 2015;22:R253–64. 3. Barth DA, Slaby O, Klec C, Juracek J, Drula R, Calin GA, et al. Current concepts of non-coding RNAs in the pathogenesis of non-clear cell renal cell carcinoma. Cancers. 2019;11:1580. 4. Liu J, Zhang W, Lin K, Ma W, Li W, Yao X. Immunological perspective on the malignant progression of renal clear cell carcinoma. Ann Transl Med. 2021;9:1544. 5. Low G, Huang G, Fu W, Moloo Z, Girgis S. Review of renal cell carcinoma and its common subtypes in radiology. World J Radio. 2016;8:484–500.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|